BridgeBio Revenue Surges, Eyes ATTR Reversal with New Antibody Program

Event summary

  • BridgeBio reported preliminary Q4 and full-year 2025 net Attruby product revenue of $146.0 million and $362.4 million, respectively.
  • Attruby has achieved rapid adoption, with 6,629 unique patient prescriptions written by 1,632 prescribers as of December 31, 2025.
  • BridgeBio announced a new TTR amyloid depleter antibody program targeting ATTR-CM disease reversal, with clinic entry expected between 2027-2028.
  • The FDA recommended pursuing traditional approval for BBP-418 (LGMD2I/R9), with an NDA submission planned for the first half of 2026.
  • BridgeBio holds approximately $587.5 million in cash, cash equivalents, and marketable securities.

The big picture

BridgeBio's strong Attruby performance and aggressive pipeline expansion demonstrate a strategy of rapid drug development and commercialization within the genetic disease space. The announcement of a disease-reversing antibody program signals a shift towards more ambitious therapeutic goals, potentially disrupting the ATTR-CM treatment landscape. The company's substantial cash reserves provide flexibility to fund these initiatives and potentially launch multiple new therapies, but also increase pressure to deliver on ambitious timelines.

What we're watching

Clinical Timelines
The success of the new TTR amyloid depleter antibody program hinges on its ability to meet the projected 2027-2028 clinic entry timeline, which will dictate the potential for disease reversal and a significant expansion of BridgeBio's ATTR-CM market share.
Regulatory Risk
While the FDA’s recommendation for traditional approval of BBP-418 is positive, the ultimate approval and subsequent commercial success remain contingent on favorable review of the full NDA submission and data.
Commercial Momentum
Attruby’s current rapid adoption rate may not be sustainable, and the company must demonstrate continued physician and patient buy-in to maintain its position as the first-choice therapy for ATTR-CM.

Related topics

Revenue Growth Drug Development Biotechnology